In this update video, Alfred Garfall, MD, examines the latest advances in multiple myeloma therapy for newly diagnosed multiple myeloma (MM) as reflected at ASH 2016, with a focus on induction therapy and maintenance following autologous stem cell transplantation (ASCT) with high-dose melphalan. The study of interest in induction therapy was SWOG S0777, which found long-term benefit for patients receiving lenalidomide, bortezomib and dexamethasone (RVD) induction-now the standard of care. Studies of ASCT/high-dose melphalan determined a clear survival benefit to patients in every subgroup analyzed, including patients with severe renal impairment. Dr. Garfall also reviews ongoing studies at Penn and considers the future of immunotherapy as first-line therapy in MM.

Related Links: